Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies
10.1007/s13139-017-0484-7
- Author:
Yoori CHOI
1
;
Seunggyun HA
;
Yun Sang LEE
;
Yun Kyung KIM
;
Dong Soo LEE
;
Dong Jin KIM
Author Information
1. Department of Nuclear Medicine, College of Medicine, Seoul National University, 110-744, 28 Yongon-Dong, Jongno-Gu, Seoul, South Korea. dsl@plaza.snu.ac.kr
- Publication Type:Review
- Keywords:
Tau;
Alzheimer's disease;
Tauopathy;
Pet;
Imaging ligands;
Radiopharmaceutical
- MeSH:
Alzheimer Disease;
Brain;
Brain Injury, Chronic;
Chromosomes, Human, Pair 17;
Diagnosis, Differential;
Disease Progression;
Frontotemporal Dementia;
Frontotemporal Lobar Degeneration;
Ligands;
Neurodegenerative Diseases;
Neurofibrillary Tangles;
Parkinsonian Disorders;
Peptides;
Plaque, Amyloid;
Supranuclear Palsy, Progressive;
tau Proteins;
Tauopathies
- From:Nuclear Medicine and Molecular Imaging
2018;52(1):24-30
- CountryRepublic of Korea
- Language:English
-
Abstract:
The pathological features of Alzheimer's disease are senile plaques which are aggregates of β-amyloid peptides and neurofibrillary tangles in the brain. Neurofibrillary tangles are aggregates of hyperphosphorylated tau proteins, and these induce various other neurodegenerative diseases, such as progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobar degeneration, frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and chronic traumatic encephalopathy. In the case of Alzheimer's disease, the measurement of neurofibrillary tangles associated with cognitive decline is suitable for differential diagnosis, disease progression assessment, and to monitor the effects of therapeutic treatment. This review discusses considerations for the development of tau ligands for imaging and summarizes the results of the first-in-human and preclinical studies of the tau tracers that have been developed thus far. The development of tau ligands for imaging studies will be helpful for differential diagnosis and for the development of therapeutic treatments for tauopathies including Alzheimer's disease.
